Drugs / cytokine-induced killer cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02496988 | Jul 2015 → Jul 2028 expected | malignant glioma | The First People's Hospital of Changzhou | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cytokine-induced killer cells | “The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced...” NCT02496988 ↗ |
| Known as | CIK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02496988 ↗ |
| Modality | Cell therapy | “Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat” NCT02496988 ↗ |
| Route | Intravenous | “Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat” NCT02496988 ↗ |